In addition to its apoptosis-inducing, EGFR-blocking activity, cetuximab directs the ADCC mechanism at tumor cells, using primarily natural killer (NK) cells to maximize antitumor effects and thereby representing the first immunotherapy in SCCHN (Figure 2) (20, 24, 30, 31). Here, EGFR is linked to neoplasm.